ACTRN12617001640392进行中（未招募）1 期
A Phase 1, Open-Label, Randomised, Two-Way Crossover Study to Assess the Pharmacokinetics, Relative Bioavailability and Food-Effect of a Single Dose of an Immediate Release and Extended Release Formulation of Propagermanium in Healthy Volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 50 Years（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
不适用
A Phase I, open-label, randomized, two-way crossover study to investigate the effects of morning versus evening repeated dosing on the pharmacokinetics of the combination of GLPG3067, GLPG2222 and GLPG2737 in healthy female subjects.MucoviscidosisCystic FibrosisNL-OMON44378Galapagos N.V.10
已完成
1 期
A Phase 1, Randomised, Open-Label, Three-way Crossover Comparative Pharmacokinetic Study of Capsule and Tablet Dosage Forms of EMA401 Sodium Salt When Administered Orally in Healthy Adult MalesACTRN12615000074594Spinifex Pharmaceuticals Pty Ltd15
进行中（未招募）
不适用
A study in patients eligible for Calcium and Vitamin D supplementation to evaluate subject preference and acceptability of a new formulation of Calcichew D3Prevention and treatment of vitamin D and calcium deficiency and adjunct to specific osteoporosis treatment of patients who are at risk of vitamin D and calcium deficiencyMedDRA version: 18.0Level: LLTClassification code 10031289Term: Osteoporosis, unspecifiedSystem Organ Class: 100000004859MedDRA version: 18.0Level: SOCClassification code 10027433Term: Metabolism and nutrition disordersSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2014-005619-18-DETakeda Development Centre Europe Ltd.276
进行中（未招募）
1 期
A study in patients eligible for Calcium and Vitamin D supplementation to evaluate subject preference and acceptability of a new formulation of Calcichew D3EUCTR2014-005619-18-GBTakeda Development Centre Europe Ltd.276
已完成
不适用
A phase 1, open-label, randomized, 2-way crossover study to assess the effects of acid reducing agent(s) on the pharmacokinetics of a single oral dose of JNJ-64417184 in healthy adult participantsNL-OMON50152Janssen-Cilag International NV14